Last updated 5 days ago
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
700 patients around the world
Available in Brazil
Eli Lilly and Company
12Research sites
700Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histological or cytological confirmation of NSCLC.Part A Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.Part A Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection.Part B Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.Must have disease with evidence of KRAS G12C mutation.Must have known programmed death-ligand 1 (PD-L1) expression.Must have an ECOG performance status of 0 or 1.Able to swallow oral medication.Must have adequate laboratory parameters.Contraceptive use should be consistent with local regulations for those participating in clinical studies.Women of childbearing potential must have a negative pregnancy test.Women of childbearing potential must not be breastfeeding during treatment.
- Have known changes in the EGFR or ALK genes.Have another type of cancer that is progressing or required active treatment within the past 3 years before screening.Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.
Sites
Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA
Instituto D'or de Pesquisa e Ensino - Rio de Janeiro
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
Centro Paulista de Oncologia
Instituto Do Câncer Do Ceará ICC
Oncocentro de Minas Gerais
Hospital Do Cancer de Londrina
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica
Hospital Tacchini
Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul
StudySUNRAY-02
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06890598
